Jubilant Pharmova
Ticker > Company >

Jubilant Pharmova share price

Jubilant Pharmova Ltd.

NSE: JUBLPHARMA BSE: 530019 SECTOR: Pharmaceuticals & Drugs  141k   495   89

921.00
+41.10 (4.67%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 921

Today's Low

₹ 879.9

52 Week High

₹ 1309

52 Week Low

₹ 616.85

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 14669.79 Cr.

Enterprise Value

₹ 14976.59 Cr.

No. of Shares

15.93 Cr.

P/E

385.03

P/B

6.37

Face Value

₹ 1

Div. Yield

0.54 %

Book Value (TTM)

₹  144.65

CASH

₹ 36.1 Cr.

DEBT

₹ 342.9 Cr.

Promoter Holding

50.68 %

EPS (TTM)

₹  2.39

Sales Growth

-3.14%

ROE

1.32 %

ROCE

2.64%

Profit Growth

-36.67 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 19 Indices.

NFT500MOM50

Nifty500 Momentum 50
51154.75
  2206.05 (4.50686126495699%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
40784.05
  562.900000000001 (1.39951244556658%)

NIFTY500

Nifty 500
22511.4
  835.850000000002 (3.85618819360987%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
18643
  689.25 (3.83903084313861%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
16885.7
  629.400000000001 (3.87172972939722%)

NIFTYSMALLCAP250

Nifty Smallcap 250
15684.2
  603.75 (4.00352774618795%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15458.25
  575.85 (3.86933559103371%)

NFT500EQUAL

Nifty 500 Equal Weight
13296.75
  510.200000000001 (3.99013025405603%)

NIFTYTOTALMCAP

Nifty Total Market index
12640.6
  472.550000000001 (3.88353105057919%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

SMLCAP

S&P Bse Small Cap
49176.68
  482.93 (0.991769991015268%)

BSE HC

S&P Bse Healthcare
41998.59
  399.299999999996 (0.95987215166411%)

BSE500

S&P Bse 500
35144.23
  -268.169999999998 (-0.757277111972077%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
11351.79
  33.5 (0.295981106686605%)

BSE1000

Bse 1000
10443.08
  -68.4799999999996 (-0.651473235181077%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SML250

S&P Bse 250 SmallCap
6343.52
  49.3200000000006 (0.783578532617346%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-3.14%
3 Year-33.84%
5 Year-25.58%

Profit Growth

1 Year-36.67%
3 Year-47.18%
5 Year-26.53%

ROE%

1 Year1.32%
3 Year2.57%
5 Year6.34%

ROCE %

1 Year2.64%
3 Year3.56%
5 Year6.52%

Debt/Equity

0.1452

Price to Cash Flow

102.44

Interest Cover Ratio

2.3946

CFO/PAT (5 Yr. Avg.)

1.43301682320157

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 50.68 0.00
Dec 2024 50.68 0.00
Sep 2024 50.68 0.00
Jun 2024 50.68 0.00
Mar 2024 50.68 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 59.765 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.43301682320157.
  • The company has a high promoter holding of 50.68%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.24980529856399.

 Limitations

  • The company has shown a poor profit growth of -47.18343712341% for the Past 3 years.
  • The company has shown a poor revenue growth of -33.8382881923691% for the Past 3 years.
  • Company has a poor ROE of 2.56951664282011% over the past 3 years.
  • Company has a poor ROCE of 3.55591725790731% over the past 3 years
  • The company is trading at a high PE of 385.03.
  • The company is trading at a high EV/EBITDA of 99.7468.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 175.2 205.8 166.7 165.7 196
Total Expenditure 175.9 193.6 165.5 171.8 185
Operating Profit -0.7 12.2 1.2 -6.1 11
Other Income 19 50.1 19.5 43.8 18.4
Interest 8.3 8.1 7.6 7.8 7.4
Depreciation 12.3 12.7 13.1 13.3 13.3
Exceptional Items 0 0 -11.2 0 0
Profit Before Tax -2.3 41.5 -11.2 16.6 8.7
Tax 0.1 9 -1 6.1 3.4
Profit After Tax -2.4 32.5 -10.2 10.5 5.3
Adjusted EPS (Rs) -0.15 2.04 -0.64 0.66 0.33

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 3139.9 2709.5 725.73 810.1 784.7
Total Expenditure 2769 2282.44 719.27 807 768.2
Operating Profit 370.9 427.06 6.46 3.1 16.5
Other Income 173.23 47.88 126.16 137.9 103.4
Interest 136.2 101.8 10.99 18.5 29.9
Depreciation 107.4 99.97 36.91 43.2 48.3
Exceptional Items -1.7 0 0 0 0
Profit Before Tax 298.84 273.17 84.72 79.3 41.7
Tax -22.3 58.69 4.23 29.4 10.1
Net Profit 321.14 214.48 80.49 49.9 31.6
Adjusted EPS (Rs.) 20.16 13.47 5.05 3.14 1.99

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 15.93 15.93 15.93 15.9 15.9
Total Reserves 2591.37 1266.52 2423.14 2398.6 2358.6
Borrowings 1327.91 420 174 174 246.5
Other N/C liabilities 122.95 22 -5.1 41.7 43.6
Current liabilities 1375.23 120.15 252.26 361.2 315.4
Total Liabilities 5433.39 1844.6 2860.23 2991.4 2980
Assets
Net Block 1864.72 127.08 636.51 687.4 711.3
Capital WIP 58.41 0.33 35.26 47 37
Intangible WIP 0.68 0 0 0 0
Investments 1764.03 1645.98 1645.75 1656.6 1656.9
Loans & Advances 16.03 4.96 13.98 18.6 24.3
Other N/C Assets 7.39 0 2.92 3 9.9
Current Assets 1722.13 66.25 525.81 578.8 540.6
Total Assets 5433.39 1844.6 2860.23 2991.4 2980
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 298.84 273.17 84.72 79.3 41.7
Adjustment 103.01 196.45 -48.68 -35.2 48.2
Changes in Assets & Liabilities -65.06 181.36 -3.42 -91.8 65.5
Tax Paid -20.03 -42.6 -19.38 -17.4 -12.2
Operating Cash Flow 316.76 608.38 -3.55 -65.1 143.2
Investing Cash Flow -197.71 116.89 93.1 31.1 -40.3
Financing Cash Flow -41.05 -781.65 -107.37 22.5 -77.8
Net Cash Flow 78 -56.37 -17.82 -11.5 25.1

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 50.68 50.68 50.68 50.68 50.68
hari shanker bhartia 0.23 0.23 0.23 0.23 0.23
hsb trustee company pvt l... 19.00 19.00 19.00 19.00 19.00
jubilant enpro private li... 1.33 1.33 1.33 1.33 1.33
kavita bhartia 0.01 0.01 0.01 0.01 0.01
mav management advisors l... 3.15 3.15 3.15 3.15 3.15
miller holdings pte ltd 3.28 3.28 3.28 3.28 3.28
nikita resources private ... 2.20 2.20 2.20 2.20 2.20
priyavrat bhartia 0.88 0.88 0.88 0.88 0.88
shamit bhartia 0.08 0.08 0.08 0.08 0.08
spb trustee company pvt l... 20.52 20.52 20.52 20.52 20.52
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 49.32 49.32 49.32 49.32 49.32
abakkus emerging opportun... 1.20 1.20 1.20 1.20 1.18
east bridge capital maste... 3.17 3.17 4.88 3.92 4.30
government pension fund g... 3.76 3.75 3.71 3.45 3.47
investor education and pr... 1.24 1.24 1.24 - 1.25
llp - - 0.27 0.28 0.21
quant mutual fund - quant... - 1.92 1.92 1.92 1.85
rekha jhunjhunwala 6.64 6.57 6.43 3.15 6.43
sbi life insurance co. lt... - - - 1.39 1.32
theleme india master fund... 1.17 1.37 1.33 1.32 1.46
estate of late mr. rakesh... - - - 3.28 -
investor education and pr... - - - 1.25 -
non resident non repartri... - - 0.74 - -
east bridge capital maste... 4.27 4.18 - - -
quant mutual fund - quant... 1.75 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Jubilant Pharmova’s arm inks Shareholders’ Agreement with Pierre Fabre SA 20 Mar, 2:59 PM Jubilant Pharmova's arm gets EIR with VAI status for Maryland facility 13 Mar, 10:59 AM Jubilant Pharmova - Quaterly Results 31 Jan, 1:05 PM Jubilant Pharmova - Quaterly Results 31 Jan, 1:05 PM Jubilant Pharmova - Quaterly Results 31 Jan, 1:05 PM Jubilant Pharmova’s arm voluntary pays $25 million term loan 27 Jan, 10:11 AM Jubilant Pharmova informs about board meeting 23 Jan, 12:17 PM Jubilant Pharmova informs about disclosure 17 Jan, 9:54 AM USFDA completes inspection at Jubilant Pharmova’s arm’s solid oral formulations facility at Salisbury 17 Jan, 9:22 AM Jubilant Pharmova informs about board meeting 25 Oct, 4:43 PM Jubilant Pharmova informs about outcome of board meeting 25 Oct, 4:33 PM Jubilant Pharmova - Quaterly Results 25 Oct, 12:26 PM Jubilant Pharmova - Quaterly Results 25 Oct, 12:26 PM Jubilant Pharmova - Quaterly Results 25 Oct, 12:26 PM Jubilant Pharmova informs about deletion of tax demand raised on Jubilant Generics 10 Oct, 4:58 PM Jubilant Pharmova informs about disclosure 20 Sep, 12:49 PM Jubilant Pharmova’s arm gets VAI classification for USA manufacturing facility 10 Sep, 4:28 PM Jubilant Pharmova’s step down arm signs, issues put option offer to Pierre Fabre Laboratories 19 Aug, 11:15 AM Jubilant Pharmova informs about AGM notice and annual report 9 Aug, 9:12 AM Jubilant Pharmova informs about disclosure 27 Jul, 12:21 PM Jubilant Pharmova informs about disclosure 20 Jul, 11:48 AM Jubilant Pharmova reports many fold jump in Q1 consolidated net profit 19 Jul, 4:25 PM Jubilant Pharmova informs about outcome of board meeting 19 Jul, 3:36 PM Jubilant Pharmova informs about press release and earnings presentation 19 Jul, 3:34 PM Jubilant Pharmova - Quaterly Results 19 Jul, 2:08 PM Jubilant Pharmova - Quaterly Results 19 Jul, 2:08 PM Jubilant Pharmova - Quaterly Results 19 Jul, 2:08 PM Jubilant Pharmova informs about completion of voluntary prepayment 25 Jun, 2:20 PM USFDA concludes audit at contract manufacturing facility of Jubilant Pharmova’s step down arm 18 Jun, 5:43 PM USFDA concludes audit at Washington manufacturing facility of Jubilant Pharmova’s arm 10 Jun, 11:53 AM Jubilant Pharmova acquires 19.89% stake in O2 Renewable Energy XVI 7 Jun, 12:29 PM Jubilant Pharmova - Quaterly Results 29 May, 2:56 PM Jubilant Pharmova - Quaterly Results 29 May, 2:56 PM Jubilant Pharmova - Quaterly Results 29 May, 2:56 PM Jubilant Pharmova’s arm approves proposal for investment in Isharays Energy 29 May, 10:42 AM USFDA concludes audit at Radiopharmaceutical manufacturing facility of Jubilant Pharmova’s arm 25 Apr, 10:14 AM Jubilant Pharmova informs about closure of manufacturing operations 18 Apr, 10:05 AM Jubilant Pharmova informs about updates on acquisition 30 Mar, 12:18 PM Jubilant Pharmova informs about change in directorate 26 Mar, 4:52 PM Jubilant Pharmova informs about analyst meeting 11 Mar, 12:38 PM Jubilant Pharmova informs about updates 17 Feb, 11:25 AM Jubilant Pharmova informs about updates 3 Feb, 2:37 PM Jubilant Pharmova informs about communication 3 Feb, 12:01 PM USFDA concludes audit at Jubilant Pharmova’s step down subsidiary’s solid dosage formulations facility 3 Feb, 11:58 AM Jubilant Pharmova - Quaterly Results 2 Feb, 2:24 PM Jubilant Pharmova - Quaterly Results 2 Feb, 2:24 PM Jubilant Pharmova - Quaterly Results 2 Feb, 2:24 PM Jubilant Pharmova informs about notice of postal ballot 27 Dec, 11:44 AM Jubilant Pharmova’s arm receives USFDA’s approval for Technetium Sulfur Colloid Injection 11 Nov, 10:32 AM Jubilant Pharmova informs about newspaper publication 30 Oct, 4:49 PM

Jubilant Pharmova Stock Price Analysis and Quick Research Report. Is Jubilant Pharmova an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Jubilant Pharmova and its performance over the period of time. Jubilant Pharmova stock price today is Rs 879.15.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Jubilant Pharmova cash from the operating activity was Rs 143.2 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Jubilant Pharmova has a Debt to Equity ratio of 0.1452 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Jubilant Pharmova , the EPS growth was -36.6747 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Jubilant Pharmova has OPM of 2.10271441315152 % which is a bad sign for profitability.
     
  • ROE: Jubilant Pharmova have a poor ROE of 1.3241 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Jubilant Pharmova is Rs 879.15. One can use valuation calculators of ticker to know if Jubilant Pharmova share price is undervalued or overvalued.
Last Updated on:
Brief about Jubilant Pharmova

Jubilant Pharmova Ltd. Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis

Jubilant Pharmova Ltd. is a leading pharmaceutical company with a strong presence in the global market. In this stock analysis, we will delve into various aspects of the company that would be of interest to long-term stock investors.

Jubilant Pharmova Ltd. Share Price

The share price of Jubilant Pharmova Ltd. reflects the market valuation of the company's stock. It is influenced by various factors such as industry trends, market conditions, and the overall performance of the company. To gain insights into the historical and current stock price, investors can refer to the price chart available on our website. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions.

Jubilant Pharmova Ltd. Balance Sheet

The balance sheet of Jubilant Pharmova Ltd. provides a snapshot of the company's financial health at a given point in time. It presents the company's assets, liabilities, and shareholders' equity. Investors can analyze the balance sheet to assess the company's solvency, liquidity, and financial stability.

Jubilant Pharmova Ltd. Annual Report

Jubilant Pharmova Ltd. publishes an annual report that provides a comprehensive overview of the company's performance throughout the year. It covers key highlights, financial statements, management discussions, and analysis of the business operations. Investors can download the annual reports from our website to gain deeper insights into the company's strategies and prospects.

Jubilant Pharmova Ltd. Dividend

Dividends are a way for companies to distribute a portion of their profits to shareholders. Jubilant Pharmova Ltd. declares dividends periodically based on its financial performance and policies. For information on historical dividends, investors can explore our pre-built screening tools that provide relevant data to aid in their analysis.

Jubilant Pharmova Ltd. Quarterly Results

Jubilant Pharmova Ltd. releases quarterly results to keep investors updated on the company's performance on a shorter time frame. These results include financial statements, management discussions, and insights into the industry dynamics. Investors can access the quarterly results as downloadable documents on our website.

Jubilant Pharmova Ltd. Stock Price

The stock price of Jubilant Pharmova Ltd. is influenced by various factors such as market demand, industry trends, and company-specific developments. By analyzing the stock price, investors can gain insights into market sentiments towards the company's prospects.

Jubilant Pharmova Ltd. Price Chart

Our website provides a comprehensive price chart that allows investors to track the historical performance of Jubilant Pharmova Ltd.'s stock. By analyzing the price movements and trends, investors can make informed decisions regarding their investments. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Jubilant Pharmova Ltd. News

Stay up to date with the latest news and developments related to Jubilant Pharmova Ltd. Our website provides a dedicated section where investors can access news articles, press releases, and industry updates concerning the company.

Jubilant Pharmova Ltd. Concall Transcripts

We understand the importance of access to concall transcripts for investors. Concalls provide valuable insights into the company's performance and future prospects. Investors can obtain and review Jubilant Pharmova Ltd.'s concall transcripts from our website.

Jubilant Pharmova Ltd. Investor Presentations

Jubilant Pharmova Ltd. conducts investor presentations to provide a deeper understanding of its business operations and growth strategies. Our website offers access to these presentations, allowing investors to stay informed about the company's developments and investment opportunities.

Jubilant Pharmova Ltd. Promoters

The promoters of Jubilant Pharmova Ltd. are key stakeholders who have a significant influence on the company's decision-making and overall direction. Investors are encouraged to learn more about the promoters and their track record to assess the company's governance and stability.

Jubilant Pharmova Ltd. Shareholders

Understanding the shareholder base of Jubilant Pharmova Ltd. provides insights into the ownership structure and potential influence on the company's decision-making. Investors can explore our pre-built screening tools to access data and information on the company's shareholders.

In addition to the comprehensive stock analysis provided, Ticker offers premium features and tools. These include DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis. These tools can assist investors in conducting a more in-depth analysis of Jubilant Pharmova Ltd.'s stock and making informed investment decisions.

By providing downloadable annual reports and quarterly results on our website, we aim to facilitate easy access to the information necessary for investors to conduct their analysis.

Jubilant Pharmova Limited ROCE

The Return on Capital Employed (ROCE) measures a company's ability to generate profits from its invested capital. As an investor, understanding this ratio is crucial in evaluating the financial performance of Jubilant Pharmova Limited. Our stock analysis page provides you with the ROCE data for the company, enabling you to make informed investment decisions. You can find this information in the financials table or ratio section above. ROCE helps you assess how efficiently Jubilant Pharmova Limited is utilizing its capital to generate returns.

Jubilant Pharmova Limited EBITDA

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a key metric that sheds light on a company's operational profitability. By considering non-operating factors, EBITDA provides a clearer picture of Jubilant Pharmova Limited's core business performance. Our stock analysis page offers you the EBITDA data for the company, allowing you to assess its operational efficiency. You can find this information conveniently in the financials table or ratio section above.

Jubilant Pharmova Limited DPS

Dividends per Share (DPS) is an essential indicator for investors seeking income from their investments. By providing the DPS data for Jubilant Pharmova Limited, our stock analysis page allows you to evaluate the company's dividend distribution over time. You can access this information in the financials table or ratio section above. DPS is an important metric as it reflects the commitment of Jubilant Pharmova Limited to sharing its profits with shareholders.

Jubilant Pharmova Limited EPS

Earnings per Share (EPS) is a crucial measure of a company's profitability. By presenting the EPS data for Jubilant Pharmova Limited, our stock analysis page enables you to gauge the company's earnings generation on a per-share basis. You can access this information in the financials table or ratio section above. EPS is widely used by investors to assess the financial performance and potential future growth of Jubilant Pharmova Limited. 

Jubilant Pharmova Reserves Analysis

From March 2020 to March 2024, Jubilant Pharmova's total reserves displayed significant fluctuations, starting at Rs 2,591.37 Cr in March 2020, dipping to Rs 1,266.52 Cr in March 2021, and making a recovery to Rs 2,423.14 Cr in March 2022. As of March 2023, reserves are slightly reduced at Rs 2,398.60 Cr and further to Rs 2,358.60 Cr in March 2024, indicating a trend of moderate stabilization.

Jubilant Pharmova Debt Insight

The borrowing trend shows a sharp decrease from Rs 1,327.91 Cr in March 2020 to Rs 420 Cr in March 2021 and then substantially dropping to Rs 174 Cr by March 2022. The amount remained steady at Rs 174 Cr in March 2023 before seeing a slight increase to Rs 246.50 Cr in March 2024.

Jubilant Pharmova Assets Overview

Jubilant Pharmova's total assets align closely with its liabilities, maintaining a balanced sheet from Rs 5,433.39 Cr in March 2020, dipping to its lowest at Rs 1,844.60 Cr in March 2021, before gradually increasing to Rs 2,980 Cr by March 2024. Notably, the investments remain relatively stable at around Rs 1,656.90 Cr by March 2024.

This data is an analysis for the Standalone Balance Sheet of the company. In navigating the broader financial landscape, investors frequently regard such detailed balance sheet analytics as a cornerstone in screening potential investment opportunities across various sectors or considering IPOs on indexes like NSE/BSE.

Read More
X